Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor Conferen ...

Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable safety profile, dose limiting toxicity dose level has not been identified in doses up to 250 mg/day Preclinical posters strengthen the NXP900 clinical development strategy as single agent in biomarker-targeted cancers and in combination with market leading therapies to overcome resistance in NSCLC Fort Lee, NJ ...

Core Viewpoint - Nuvectis Pharma, Inc. is advancing its clinical-stage drug candidate NXP900, a novel YES1/SRC kinase inhibitor, with upcoming presentations at the 2025 American Association for Cancer Research Meeting, highlighting its potential in treating advanced solid tumors and overcoming drug resistance in non-small cell lung cancer (NSCLC) [1][2]. Group 1: NXP900 Development - NXP900 is currently in a Phase 1a dose escalation study, demonstrating potent single-agent activity and synergy with ALK inhibitors in ALK-resistant NSCLC models [2][4]. - The drug targets YAP1 signaling in NSCLC cell lines and shows sensitivity in endocrine therapy-resistant luminal A breast cancer cell lines [2][4]. Group 2: Presentation Details - Nuvectis will present findings related to NXP900 in various sessions at the 2025 AACR Meeting, including "First-in-Human Phase I Clinical Trials" and "Drug Resistance in Molecular Targeted Therapies," scheduled for April 29th [3]. - Specific presentation times include sessions from 9:00 AM to 12:00 PM and 2:00 PM to 5:00 PM on the same day [3]. Group 3: Company Overview - Nuvectis Pharma, Inc. focuses on developing innovative precision medicines for serious unmet medical needs in oncology, with two clinical-stage candidates: NXP800 and NXP900 [4]. - NXP800 is an oral small molecule GCN2 activator in trials for platinum-resistant ovarian carcinoma and cholangiocarcinoma, while NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases [4].